Find and Pitch Jounalists, Get Your Story Covered

Tags: leadership pharma Research & Development research-development biotech

	Profile	Recent Articles on Subject
1	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	3 closely watched drugs that failed in the clinic - 11 days ago The big rebrand: Why these 4 biopharmas changed their name this year - 23 days ago Where are they now? 4 biotechs that soared then crashed during the pandemic - about 1 month ago Pharma takes aim at a wily foe — the Epstein-Barr virus - about 2 months ago 2024 PharmaVoice 100s: Rare Disease Warriors - about 2 months ago 2024 PharmaVoice 100s: Trailblazers - 2 months ago Who’s winning in biotech’s tight market? - 4 months ago What 3 layoff stories reveal about pharma’s troubles - 4 months ago Pharma’s ‘it’ therapy — a new drug class gaining steam - 4 months ago What pharma has learned from AI - 5 months ago Pharma’s R&D gamble: picking pipeline winners in a risky field - 7 months ago Where competition is heating up in pharma - 7 months ago The biggest questions hanging over pharma in 2024 - 11 months ago Pharma execs sound off on trends and policies they’re tracking in 2024 - 12 months ago PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials - 12 months ago 10 of our most read articles in 2023 - about 1 year ago Does BioMarin’s CEO shuffle signal bigger changes ahead? - about 1 year ago PharmaVoice 100s: Entrepreneurs - about 1 year ago PharmaVoice 100s: Clinical trial gurus - about 1 year ago
2	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Oncology, obesity and more: Where pharma R&D is headed in 2025 - 11 days ago From Mr. Mucus to the Super Bowl, pharma tries offbeat marketing strategies - about 1 month ago Can BioNTech sustain a post-COVID mRNA pipeline? Oncology is the next hope. - 5 months ago Read to lead: 6 books pharma execs swear by - 5 months ago Behind the powerful computations, AI’s role in pharma is still beset by challenges - 7 months ago Behind Big Pharma’s layoffs — is there an end in sight? - 7 months ago 4 offbeat biotechs making a splash in the life sciences - 8 months ago As antimicrobial resistance looms large, a nonprofit teams up with Big Pharma to intervene - 9 months ago These biotech hotspots are ripe for IPOs - 10 months ago COVID vaccine giants Moderna and Pfizer employ divergent tactics for the next chapter - 10 months ago
3	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Up and down the ladder: The latest comings and goings - 14 days ago STAT+: Up and down the ladder: The latest comings and goings - 21 days ago STAT+: Pharmalittle: We’re reading about GSK leaving BIO, an AbbVie schizophrenia drug failing, and more - about 2 months ago STAT+: Up and down the ladder: The latest comings and goings - about 2 months ago STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - about 2 months ago STAT+: Up and down the ladder: The latest comings and goings - about 2 months ago STAT+: Pharmalittle: We’re reading about pharma risks in China, mitigating shortages, and more - about 2 months ago STAT+: Up and down the ladder: The latest comings and goings - 2 months ago STAT+: Up and down the ladder: The latest comings and goings - 2 months ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Pharmalittle: We’re reading about Moderna R&D cuts, Lilly plant investments and more - 4 months ago STAT+: Up and down the ladder: The latest comings and goings - 4 months ago STAT+: Up and down the ladder: The latest comings and goings - 8 months ago STAT+: Up and down the ladder: The latest comings and goings - 9 months ago STAT+: Pharmalittle: We’re reading about biotech startups, Pfizer’s RSV vaccine, and more - 9 months ago STAT+: Pharmalittle: We’re reading about Biocon eyeing weight loss drugs, Sanofi layoffs, and more - 9 months ago STAT+: Up and down the ladder: The latest comings and goings - 9 months ago STAT+: Pharmalittle: We’re reading about BIO cutting ties with WuXi, EU pharma rules, and more - 10 months ago STAT+: Pharmalittle: FDA approvals rebound, abortion pill orders rise, and more news - 12 months ago STAT+: Pharmalittle: Pfizer is leaving the BIO trade group; CVS drug-pricing plan may not lower costs for consumers - about 1 year ago STAT+: Pharmalittle: Bioscience job market is upside down; Sanofi and Regeneron’s blockbuster Dupixent may find bigger market - about 1 year ago STAT+: Pharmalittle: Life sciences deals on track to hit lowest point since 2017; EU regulators order Illumina to divest Grail - about 1 year ago
4	Lizzy Lawrence STAT News Medical devices reporter at STATnews. Loves news tips. medical reportingnews	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - about 2 months ago
5	Sarah Owermohle STAT News Health reporter @STATNews. Covers Biden's agenda. Washington, District of Columbia health policyjournalism	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - about 2 months ago
6	John Wilkerson STAT News STAT Washington correspondent. Healthcare Journalism	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - about 2 months ago
7	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - about 2 months ago STAT+: Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline - 10 months ago
8	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - about 2 months ago
9	Matthew Herper STAT News Writes at STAT. Biology's century. Undisclosed biologydatajournalism	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - about 2 months ago
10	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - about 2 months ago

Journalists covering BioPharma, Pharma